November 9, 2023 06:36 AM ESTUpdated November 10, 11:34 AM

Merck KGaA’s Bavencio no longer 'alone' in bladder cancer market, but growth opportunity remains

Ayisha Sharma

News Reporter

Merck KGaA’s Bavencio will face its first competitor in first-line bladder cancer in the form of Seagen and Astellas’ Padcev plus Merck’s Keytruda, but the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Merck KGaA’s Bavencio no longer 'alone' in bladder cancer market, but growth opportunity remains

Ayisha Sharma

News Reporter

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

At Jefferies, all that manufacturers want to talk about is GLP-1s

Are programs with compounded GLP-1s safe for your population?

Mer­ck KGaA’s Baven­cio no longer 'alone' in blad­der can­cer mar­ket, but growth op­por­tu­ni­ty re­mains

Ayisha Sharma

News Reporter

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Merck KGaA’s Bavencio no longer 'alone' in bladder cancer market, but growth opportunity remains

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

At Jefferies, all that manufacturers want to talk about is GLP-1s

Are programs with compounded GLP-1s safe for your population?